Center for Scientific Review; Notice of Closed Meetings, 8876-8877 [2023-02859]
Download as PDF
8876
Federal Register / Vol. 88, No. 28 / Friday, February 10, 2023 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Request for Information on Promising
Practices for Advancing Health Equity
for Intersex Individuals
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services (HHS).
ACTION: Notice of Request for
Information.
AGENCY:
Through this Request for
Information (RFI), the Office of the
Assistant Secretary for Health (OASH),
Department of Health & Human
Services, invites feedback from
stakeholders throughout the scientific
research community, clinical practice
communities, patient and family
advocates, scientific or professional
organizations, federal partners, internal
HHS stakeholders, and other interested
constituents on the development of a
report on promising practices for
advancing health equity for intersex
individuals. The overarching purpose of
the report on the promising practices for
advancing health equity for intersex
individuals is to ensure access to
affirming, high-quality care for intersex
people who live in America.
DATES: The Office of the Assistant
Secretary for Health’s Request for
Information is open for public comment
for a period of 4 weeks. Comments must
be received on or before COB (5 p.m.
ET) March 13, 2023, to ensure
consideration. After the public comment
period has closed, the comments
received by OASH will be considered in
a timely manner in the development of
the report on the promising practices for
advancing health equity for intersex
individuals.
SUMMARY:
Please see the
supplementary information to view the
questions. It is strongly encouraged to
submit comments by email to Adrian
Shanker, Adrian.shanker@hhs.gov,
‘‘notices for advancing health equity for
intersex individuals’’ in the subject line.
FOR FURTHER INFORMATION CONTACT:
Adrian Shanker, Adrian.shanker@
hhs.gov or by phone at (202) 961–6483.
SUPPLEMENTARY INFORMATION:
Background: The OASH oversees the
Department’s key public health offices
and programs, several Presidential and
Secretarial advisory committees, 10
regional health offices across the nation,
and the Office of the Surgeon General
and the U.S. Public Health Service
Commissioned Corps. On June 15, 2022,
President Biden signed Executive Order
(E.O.) 14075, Advancing Equity for
lotter on DSK11XQN23PROD with NOTICES1
ADDRESSES:
VerDate Sep<11>2014
17:41 Feb 09, 2023
Jkt 259001
Lesbian, Gay, Bisexual, Transgender,
Queer and Intersex Individuals. E.O.
14075 built upon the historic progress
the Biden-Harris Administration has
made in advancing LGBTQI+ Equity and
outlined policy actions to safeguard
health care for transgender people,
support programs designed to prevent
youth suicide and preventing ‘so called’
conversion therapy. The Executive
Order also directed HHS to issue a
report on promising practices for
advancing health equity for intersex
individuals.
Request for Comments on the Report
Development on Promising Practices for
Advancing Health Equity for Intersex
Individuals: The OASH invites input
from stakeholders throughout the
scientific research community, clinical
practice communities, patient and
family advocates, scientific or
professional organizations, federal
partners, internal HHS stakeholders,
and other interested members of the
public on the two questions highlighted
below. This input will serve as a
valuable element in the development of
the report, and the community’s time
and consideration are highly
appreciated.
• What do you see as the current
clinical, research, or policy gaps that
you are hoping this report addresses?
• What recent or ongoing research,
innovative clinical approaches or policy
actions do you think is important for us
to know about as we begin this work?
The OASH seeks comments and/or
suggestions from all interested parties
on promising practices for advancing
health equity for intersex individuals.
Responses to this RFI are voluntary.
Do not include any proprietary,
classified, confidential, trade secret, or
sensitive information in your response.
The responses will be reviewed by
OASH staff, and individual feedback
will not be provided to any responder.
The Government will use the
information submitted in response to
this RFI at its discretion. The
Government reserves the right to use
any submitted information on public
HHS websites; in reports; in summaries
of the state of the science; in any
possible resultant solicitation(s),
grant(s), or cooperative agreement(s); or
in the development of future funding
opportunity announcements.
This RFI is for information and
planning purposes only and should not
be construed as a solicitation for
applications or proposals, or as an
obligation in any way on the part of the
United States Federal Government, the
HHS, or individual HHS Agencies and
Offices to provide support for any ideas
identified in response to it. The Federal
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
Government will not pay for the
preparation of any information
submitted or for the Government’s use
of such information.
No basis for claims against the U.S.
Government shall arise as a result of a
response to this RFI or from the
Government’s use of such information.
Additionally, the Government cannot
guarantee the confidentiality of the
information provided.
Dated: February 6, 2023.
Rachel L. Levine,
Assistant Secretary for Health.
[FR Doc. 2023–02826 Filed 2–9–23; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Healthcare and Health Disparities Study
Section.
Date: March 9–10, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Tara Roshell Earl, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1007C,
Bethesda, MD 20892, (301) 402–6857, earltr@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–20–
117: Maximizing Investigators Research
Award (MIRA) for Early Stage Investigators
(R35—Clinical Trial Optional).
Date: March 9–10, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\10FEN1.SGM
10FEN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 28 / Friday, February 10, 2023 / Notices
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Robert O’Hagan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (240) 909–6378, ohaganr2@
csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Expanding Collaborative Implementation
Science to Address Social and Structural
Determinants of Health and Improve HIV
Outcomes.
Date: March 9, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Wenjuan Wang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 3154,
Bethesda, MD 20892, (301) 480–8667,
wangw22@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Genes, Genomes and Genetics.
Date: March 9–10, 2023.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Linda Wagner Jurata,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 496–8032, linda.jurata@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 22–
204: Development of Animal Models and
Related Materials for HIV/AIDS Research.
Date: March 9, 2023.
Time: 10:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Liliana Norma BertiMattera, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
RM 6158, MSC 7890, Bethesda, MD 20892,
301–827–7609, liliana.berti-mattera@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Auditory Neuroscience and
Learning and Memory Processes.
Date: March 9, 2023.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: John Bishop, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5182,
VerDate Sep<11>2014
17:41 Feb 09, 2023
Jkt 259001
MSC 7844, Bethesda, MD 20892, (301) 408–
9664, bishopj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA Panel:
Maternal Health Research COE Hubs.
Date: March 9, 2023.
Time: 11:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jennifer Ann Sanders,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 496–3553, jennifer.sanders@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Respiratory, Cardiac, and
Circulatory Sciences.
Date: March 9, 2023.
Time: 1:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Richard D. Schneiderman,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4138,
Bethesda, MD 20817, 301–402–3995,
richard.schneiderman@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Special Emphasis Panel on Topics
in Endocrinology and Metabolism.
Date: March 10, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Victoria Martinez Virador,
Ph.D., Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–594–4703,
victoria.virador@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–22–
254: Limited Competition: IDeA Regional
Entrepreneurship Development (I–RED)
Program (STTR) (UT2).
Date: March 10, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Joonil Seog, SCD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 301–402–9791, joonil.seog@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; SBIR/STTR
Applications in Drug Discovery and
Development.
Date: March 13, 2023.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
8877
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015.
Contact Person: Sergei Ruvinov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4158,
MSC 7806, Bethesda, MD 20892, 301–435–
1180, ruvinser@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 7, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–02859 Filed 2–9–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; CTSA RC2 High Impact
Specialized Innovation Programs Review
Meeting.
Date: May 18, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jing Chen, Ph.D., Scientific
Review Officer, Office of Scientific Review,
National Center for Advancing Translational
Sciences, National Institutes of Health, 6701
Democracy Boulevard, Room 1037, Bethesda,
MD 20892, (301) 827–3268, chenjing@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
E:\FR\FM\10FEN1.SGM
10FEN1
Agencies
[Federal Register Volume 88, Number 28 (Friday, February 10, 2023)]
[Notices]
[Pages 8876-8877]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-02859]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Healthcare Delivery and Methodologies
Integrated Review Group; Healthcare and Health Disparities Study
Section.
Date: March 9-10, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Tara Roshell Earl, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1007C, Bethesda, MD 20892, (301)
402-6857, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR-20-117: Maximizing Investigators Research Award (MIRA)
for Early Stage Investigators (R35--Clinical Trial Optional).
Date: March 9-10, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 8877]]
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Robert O'Hagan, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 909-6378,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Expanding Collaborative Implementation Science to
Address Social and Structural Determinants of Health and Improve HIV
Outcomes.
Date: March 9, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Wenjuan Wang, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institute of Health, 6701
Rockledge Drive, Room 3154, Bethesda, MD 20892, (301) 480-8667,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Fellowships: Genes, Genomes and Genetics.
Date: March 9-10, 2023.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Linda Wagner Jurata, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892, (301) 496-8032,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR 22-204: Development of Animal Models and Related
Materials for HIV/AIDS Research.
Date: March 9, 2023.
Time: 10:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Liliana Norma Berti-Mattera, Ph.D., Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, RM 6158, MSC 7890, Bethesda, MD 20892,
301-827-7609, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Auditory Neuroscience and Learning and
Memory Processes.
Date: March 9, 2023.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive Bethesda, MD 20892 (Virtual Meeting).
Contact Person: John Bishop, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5182, MSC 7844, Bethesda, MD 20892, (301) 408-
9664, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; RFA Panel: Maternal Health Research COE Hubs.
Date: March 9, 2023.
Time: 11:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jennifer Ann Sanders, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496-3553,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Respiratory, Cardiac, and Circulatory
Sciences.
Date: March 9, 2023.
Time: 1:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Richard D. Schneiderman, Ph.D., Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4138, Bethesda, MD 20817, 301-
402-3995, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Special Emphasis Panel on Topics in
Endocrinology and Metabolism.
Date: March 10, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Victoria Martinez Virador, Ph.D., Scientific
Review Officer, Center for Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301-594-4703, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR-22-254: Limited Competition: IDeA Regional
Entrepreneurship Development (I-RED) Program (STTR) (UT2).
Date: March 10, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Joonil Seog, SCD, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892, 301-402-9791,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; SBIR/STTR Applications in Drug Discovery and Development.
Date: March 13, 2023.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road NW, Washington, DC 20015.
Contact Person: Sergei Ruvinov, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4158, MSC 7806, Bethesda, MD
20892, 301-435-1180, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: February 7, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-02859 Filed 2-9-23; 8:45 am]
BILLING CODE 4140-01-P